



TF

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

In re Application of: :  
KAESEMEYER : Confirmation No. 7600  
Serial No. 10/763,358 : Group Art Unit: 1614  
Filed: January 23, 2004 : Examiner: Not Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES


Date Mailed: November 2, 2006

I HEREBY CERTIFY THAT THIS SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE VIA FIRST CLASS MAIL UNDER 37 CFR 1.8 AND IS ADDRESSED TO MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450

Kathleen Pujol  
(Typed or printed name of person mailing paper or fee)

\_\_\_\_\_  
(Signature of person mailing paper or fee)

Documents Mailed:  
Supplemental Information Disclosure Statement (2 pages)  
Form PTO-1449 (5 pages)  
References Cited (101)  
Certificate of Mailing  
Postcard



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

KAESEMEYER

Serial No. 10/763,358

Filed: January 23, 2004

:

:

:

:

Confirmation No. 7600

Group Art Unit: 1614

Examiner: Not Yet Assigned

For: COMPOSITIONS COMPRISING ARGININE AND NITRATES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.


The undersigned asserts that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

AUTHORIZATION

No fee is required. The Commissioner is hereby authorized to charge any additional fees which may be required for this submission, or credit any overpayment to Deposit Account No. 50-0436.


Respectfully submitted,

PEPPER HAMILTON LLP

A handwritten signature in black ink, appearing to read 'Raymond A. Miller', with a long horizontal flourish extending to the right.

Raymond A. Miller  
Registration No. 42,891

Pepper Hamilton LLP  
500 Grant Street, 50<sup>th</sup> Floor  
Pittsburgh, PA 15219  
Telephone: (412) 454-5000  
Facsimile: (412) 281-0717  
Date: November 2, 2006



PATENT

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>		
				Application Number	10/763,358	
				Filing Date	January 23, 2004	
				First Named Inventor	Kaesemeyer	
				Group Art Unit	1614	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	5	Attorney Docket Number	126625.00901	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	A1	5,286,739		Kilbourn et al.	02-15-1994	
	A2	5,281,627		Griffith	01-25-1994	
	A3	5,273,875		Griffith	12-28-1993	
	A4	5,266,594		Dawson et al.	11-30-1993	
	A5	5,196,195		Griffith	03-23-1993	
	A6	5,158,883		Griffith	10-27-1992	
	A7	5,132,453		Griffith	07-21-1992	
	A8	5,132,407		Stuehr et al.	07-21-1992	
	A9	5,059,712		Griffith	10-22-1991	
	A10	4,686,211		Hara et al.	08-11-1987	
	A11	5,428,070		Cooke et al.	06-27-1995	
	A12	5,830,879		Isner	11-03-1998	
	A13	5,795,898		Brown et al.	08-18-1998	
	A14	5,543,430		Kaesemeyer	08-06-1996	
	A15	5,428,070		Cooke et al.	06-27-1995	
	A16	5,147,650		Fregly et al.	09-15-1992	
	A17	4,920,098		Cotter et al.	04-24-1990	
	A18	5,106,836		Clemens et al.	04-21-1992	
	A19	5,171,217		March et al.	12-15-1992	
	A20	5,278,189		Rath et al.	01-11-1994	
	A21	5,366,738		Rork et al.	11-22-1994	
	A22	5,620,876		Davis et al.	04-15-1997	
	A23	5,650,418		Rath et al.	07-22-1997	
	A24	5,852,058		Cooke et al.	12-22-1998	
	A25	5,861,168		Cooke et al.	01-19-1999	
	A26	5,891,459		Cooke et al.	04-06-1999	
	A27	5,595,970		Garfield et al.	07-01-1997	
	A28	6,425,881		Kaesemeyer	07-30-2002	
	A29	5,824,331		Usala	10-20-1998	
	A30	5,895,663		Irwin et al.	04-20-1999	
	A31	4,940,580		Sangekar et al.	07-10-1990	
	A32	4,983,398		Gaylord et al.	01-08-1991	
	A33	4,967,658		Townsend	11-06-1990	
	A34	5,582,838		Rork et al.	12-10-1996	
	A35	5,508,045		Garfield et al.	01-21-1997	
	A36	5,643,944		Garfield et al.	07-01-1997	
	A37	5,470,847		Garfield et al.	11-28-1995	
	A38	5,681,278		Igo et al.	10-28-1997	
	A39	6,475,530		Kuhrts	11-05-2002	
	A40	3,291,689		Nordmann	12-13-1996	
	A41	6,328,979		Yamashita et al.	12-11-2001	
	A42	6,953,593		Kuhrts	10-11-2005	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)					<b>Complete if Known</b>						
					Application Number		10/763,358				
					Filing Date		January 23, 2004				
					First Named Inventor		Kaesemeyer				
					Group Art Unit		1614				
Examiner Name		Not Yet Assigned									
Sheet	2	of	5	Attorney Docket Number		126625.00901					
<b>FOREIGN PATENT DOCUMENTS</b>											
Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			T	
		Office	Number	Kind Code (if known)							
	B1	WO	99/18952		Brigham and Women's Hospital, Inc.	04-22-1999					
	B2	WO	99/47153		Brigham and Women's Hospital, Inc.	09-23-1999					
	B3	WO	00/03746		Brigham and Women's Hospital, Inc.	01-27-2000					
	B4	WO	00/56403		Brigham and Women's Hospital, Inc.	09-28-2000					
	B5	EP	0546796	A1	Ajinomoto	06-16-1993					
	B6	WO	96/00112	A1	Cormedics Corp.	01-04-1996					
	B7	WO	02/00212	A1	Nitrosystems, Inc.	01-03-2002					
	B8	WO	90/11070		Pitman-Moore, Inc.	10-04-1990					
	B9	EP	0350246		Takeda Chemical Industries	01-10-1990					
	B10	WO	01/35953		Kuhrts	05-25-2001					
	B11	WO	00/56328		Enos Pharmaceuticals, Inc.	09-20-2000					
	B12	WO	98/44893		Kaesemeyer	10-15-1998					
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>											
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.									T
	C1	PATEL et al., Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells, 1996, Free Radical Biol. & Med. 20(5):629 (ABSTRACT)									
	C2	LEE et al., Inhibition of Cerebral Neurogenic Vasodilation by L-Glutamine and Nitric Oxide Synthase Inhibitors and Its Reversal by L-Citrulline, 1996, J. Pharmacology and Exper. Thera. 276(2):353-358									
	C3	ABOU-MOHAMED et al., L-Arginine in the Development and Reversal of Tolerance to Nitroglycerin, 1996, FASEB J. 10(3):A569(no.3280) (ABSTRACT)									
	C4	XIA et al., Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury, June 1996, Proc. Natl. Acad. Sci. USA 93:6770-6774									
	C5	RECTOR et al., Randomized, Double-Blind, Placebo-Controlled Study of Supplemental Oral L-Arginine in Patients with Heart Failure, June 15, 1996, Circulation 93(12):2135-2141									
	C6	JEREMY et al., Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit, Aug. 1, 199, Circulation 94(3):498-506									
	C7	BLOCK et al., Hypoxia Inhibits L-Arginine Uptake by Pulmonary Artery Endothelial Cells, 1995, Am. J. Physiol. 269:L574-L580 (ABSTRACT)									
	C8	HECKER et al., Inhibition of Arginase by NG-Hydroxy-L-Arginine in alveolar macrophages: Implications for the Utilization of L-Arginine for Nitric Oxide Synthesis, Feb. 13, 1995, FEBS Letters 359(2-3):251-254									
	C9	CLOAREE-BLANCHARD et al., Rapid Development of Nitrate Tolerance in Healthy Volunteers: Assessment Using Spectral Analysis of Short-Term Blood Pressure and Heart Rate Variability, 1994, J. Cardio. Pharm. 24:266-273 (ABSTRACT)									
	C10	CELERMAJER et al., 1994, Role of Endothelium in the Maintenance of Low Pulmonary Vascular Tone in Normal Children, 1994, Circulation 89(5):2041-2044 (ABSTRACT)									
	C11	BOESGAARD et al., Nitrate Tolerance in Vivo is Not Associated with Depletion of Arterial or Venous Thiol Levels, Jan. 1994, Circ. Res. 74(1):115-120									
	C12	CASTILLO et al., The Plasma Flux and Oxidation rate of Ornithine Adaptively Decline with Restricted with Restricted Arginine Intake, July 5, 1994, Proc. Natl. Acad. Sci. USA 91(14):6393-6397									
	C13	KUMAGAI et al., Nitric Oxide Increases Renal Blood Flow by Interacting with the Sympathetic Nervous System, Aug. 1994, Hypertension 24(2):220-226									

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/763,358
				<b>Filing Date</b>	January 23, 2004
				<b>First Named Inventor</b>	Kaesemeyer
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	<b>3</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	126625.00901
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
	C14	LIND et al., Endotoxin Stimulates Arginine Transport in Pulmonary Artery Endothelial Cells, 1993, Surgery 114:199-205 (ABSTRACT)			
	C15	CASTILLO et al., Splanchnic Metabolism of Dietary Arginine in Relation to Nitric-Oxide Synthesis on Normal Adult Man, Jan. 1, 1993, Proc. Natl. Acad. Sci. USA, 80(1):193-197 (ABSTRACT)			
	C16	KITAMURA et al., Nitric Oxide-Mediated Retinal Arteriolar and Arterial Dilatation Induced by Substance P., Sept. 1993, Investig. Ophthal. and Vis. Sci. 34(10):2859-2865			
	C17	MEHTA et al., Free Radicals, Antioxidants and Coronary Heart Disease, Sept. 1993, J. Myocardia Ischemia 5(8):31-33, 31-41			
	C18	WEYRICH et al., The Role of L-Arginine in Ameliorating Reperfusion Injury After Myocardial Ischemia in the Cat, July 1992, Circul. 86(1):279-287			
	C19	SCHINI et al., L-Arginine Evokes Both Endothelium-Dependent and Independent Relaxations in L-Arginine-Depleted Aortas of the Rat, 1991, Circulation Research 68:209-216 (ABSTRACT)			
	C20	MARLETTA, Nitric Oxide, Nitrovasodilators and L-Arginine-An Unusual Relationship, Jan. 1991, Western J. Med. 154(1):107-109			
	C21	MAYER et al., Brain Nitric Oxide Synthesis is a Biopterin-and Flavin-Containing Multi-Functional Oxido-Reductase, Aug. 1991, FEBS 10045, vol. 288(1,2):187-191			
	C22	ZEMBOWICZ et al., Nitric Oxide and Another Potent Vasodilator are Formed From Nq-Hydroxy-L-Arginine bu Cultured Endothelial Cells, Dec. 1991, Proc. Natl. Acad. Sci. USA, 88:11172-11176 (ABSTRACT)			
	C23	SNEDDON et al., Transport and Metabolism of L-Arginine by Bovine Aortic Endothelial Cells, Nitric Oxide From L-Arginine: A Bio-Regulatory System, 1990, Elsevier Sci. Pub., Ch. 51, p. 457 (Intro Only)			
	C24	WEIDINGER et al., Persistent Dysfunction of Regenerated Endothelium After Balloon Angioplasty of Rabbit Iliac Artery, May 1990, Circulation 81(5):1667-1679			
	C25	BREDET et al., Nitric Oxide Mediates Glutamate-Linked Enhancement of cGMP Levels in the Cerebellum, Nov. 1989, Proc. Natl. Acad. Sci. USA 86:9030-9033			
	C26	ALBINA et al., Arginine Metabolism in Wounds, 1988, Am. J. Physiol. 254:E459-E467			
	C27	FLAHERTY et al., Intravenous Nitroglycerin in Acute Myocardial Infarction, Jan. 1975, Circulation 51:132-139			
	C28	PARKER et al., The Arginine Provocative Test: An Aid in the Diagnosis of Hyposematotrepism, Aug. 1967, J. Clin. Endo. 27:1129-1136			
	C29	KNOPF et al., Plasma Growth Hormone Response to Intravenous Administration of Amino Acids, Aug. 1965, Preliminary Communication 25:1140-1144			
	C30	COOKE et al., Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit, Sept. 1990, J. Clin. Invest. 90(3):1168-1172			
	C31	IGNARRO et al., Basic Polyamino Acids Rich in Arginina, Lysine or Ornithine Cause Both Enhancement of and Refractoriness to Formation of Endothelium-Derived Nitric Oxide in Pulmonary Artery and Vein, Feb. 1989, Circ. Res. 64(2):315-329			
	C32	LIN et al., Prolonged Reduction of High Blood Pressure with Human Nitric Oxide Synthase Gene Delivery, Sept. 1997, Hypertension 30(3):part 1, pp. 307-313			
	C33	GLORIOSO et al., Effect of the HMG-CoA Reductase Inhibitors on Blood Pressure in Patients with Essential Hypertension and Primary Hypercholesterolemia, 1999, Hypertension 34:1281-1286			
	C34	CAREY et al., An Arginine-Deficient Diet in Humans Does Not Evoke Hyperammonemia or Orotic Aciduria, 1987, Am. Inst. Nutr. 117(10):1734-1739			
	C35	MATERA et al., Pharmacokinetic Study of the relative Bioavailability and Bioequivalence Afte Oral Intensive or Repeated Short Term Treatment with Two Polyamino Acid Formulations, 1993, Int. J. Clin. Pharm. Res. 13(2):93-105			
	C36	MUROHARA et al., Nitric Oxide Synthase Modulates Angiogenesis in response to Tissue Ischemia, 1998, J. Clin. Invest. 101(11):2567-2578			
	C37	KUROWSKA et al., Hypocholesterolemic properties of nitric oxide. In vivo and in vitro studies using nitric oxide donors, 1998, Biochemica et Biophysics Acta 1392:41-50			
	C38	SUN et al., Pharmacokinetic Interaction Study Between Benazepril and Amlodipine in Healthy-Subjects, 1994, Eur. J. Clin Pharm. 47(3):285 (ABSTRACT)			

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/763,358
				<b>Filing Date</b>	January 23, 2004
				<b>First Named Inventor</b>	Kaesemeyer
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	<b>4</b>	<b>of</b>	<b>5</b>	<b>Attorney Docket Number</b>	126625.00901
<b>OTHER ARTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
	C39	HARIA et al., Pravastatin, A Reappraisal of its Pharmacological Properties and Clinical Effectiveness in the Management of Coronary Heart Disease, 1997, Drugs, 53(2):299-336			
	C40	PITT et al., Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): Reduction in Atherosclerosis Progression and Clinical Events, 1995, JACC 26(5):1133-1139			
	C41	NAKAMURA et al., Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHiga Pravastatin Study), 1996, Cardiovasc. Drug Ther. 10(4):475-483 (ABSTRACT)			
	C42	AJI et al., L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL receptor Knockout Mice, 1997, Circulation 95:430-437			
	C43	COOKE et al., Arginine: A new Therapy for Atherosclerosis?, 1997, Circulation 95:311-312			
	C44	JAY et al., Modulation of Vascular Tone by Low Density Lipoproteins. Effects on L-Arginine Transport and Nitric Oxide Synthesis, 1997, Experimental Physiology, 82:349-360			
	C45	VAN BOVAN et al., Reduction of Transient Myocardial Ischemia with Pravastatin in Addition to the Conventional Treatment in Patients with Angina Pectoris, 1996, Circulation 94:1503-1505			
	C46	BYINGTON et al., Reduction in Cardiovascular Events During Pravastatin Therapy. Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program, 1995, Circulation 92:2419-2425			
	C47	PRITCHARD et al., Native Low-Density Lipoprotein Increases Endothelial Cell Nitric Oxide Synthase Generation of Superoxide Anion, 1995, Circ. Res. 77(3):510-518			
	C48	LACOSTE et al., Correction of the Increased Thrombogenic Potential with Cholesterol Reduction, 1995, Circulation 92:3172-3177			
	C49	VON DER LEYEN et al., Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene, 1995, Proc. Natl. Acad. Sci. USA 92:1137-1141			
	C50	EGASHIRA et al., Reduction in Serum Cholesterol with Pravastatin Improves endothelium-Dependent Coronary Vasomotion in Patients with Hypercholesterolemia, 1994, Circulation 89:2519-2524			
	C51	TSAO et al., Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine, 1994, Circulation 89:2176-2182			
	C52	CHEN et al., Oxidized LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function, 1993, Circulation 93:1740-1746			
	C53	HAMON et al., Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury Circulation, Sept. 1994, Circulation 90(3):1357-1362			
	C54	COOKE et al., Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta, 1991, Circulation 83:1057-1062			
	C55	WITZUM et al., Role of Oxidized Low Density Lipoprotein in Atherogenesis, 1991, J. Clin. Invest. 88:1785-1792			
	C56	MUGGE et al., Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits, 1991, Circ. Res. 69:1293-1300			
	C57	FORSTERMANN et al., Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries, 1988, Circ. Res. 62:185-191			
	C58	COHEN et al., Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia, 1988, Circ. Res. 63:903-910			
	C59	SCHWARZACHER et al., Local Intramural Delivery of L-Arginine Enhances Nitric Oxide Generation and Inhibit Lesion Formation After Balloon Angioplasty, April 1997, Circulation 95(7):1863-1869			
	C60	SELLKE et al., Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium, Aug. 1996, Am. J. Physiol. Heart Circ. Physiol. 271:H713-H720			
	C61	CUEVAS et al., Hypotensive Activity of Fibroblast Growth Factor, Nov. 1991, Science 254:1208-1210			
	C62	BASSENGE, Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators, 1994, Cardio. Drugs and Therapy 8:601-610			
	C63	SUNDERKOTTER et al., Macrophages and Angiogenesis, 1994, J. Leukoc. Biol. 55(3):410-422			

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/763,358
				<b>Filing Date</b>	January 23, 2004
				<b>First Named Inventor</b>	Kaesemeyer
				<b>Group Art Unit</b>	1614
				<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	5	of	5	<b>Attorney Docket Number</b>	126625.00901
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
	C64	WITZENBICHLER et al., Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia, Aug. 1998, Am. J. Pathol. 153(2):381-394			
	C65	BOUCK et al., How Tumors Become Angiogenic, 1996, Adv. Cancer Res. 69:135-174			
	C66	OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonists on Uptake of Cellular L-Arginine, Sept. 1998, Physiobiologist, No. 18.5 (ABSTRACT)			
	C67	OGONOWSKI et al., Effect of Nitrite Oxide Donors and Synthase Agonist Peptides on Endothelial Cell Uptake of L-Arginine, March. 1998, FASEB Journal 12(4):A442, No. 2568 (ABSTRACT)			
	C68	JIN et al., Effects of Acetylcholine and Prostacyclin on Endothelial Cell Transport of L-Arginine, March 1998, FASEB, No. 2567 (ABSTRACT)			
	C69	LAHAM et al., Local Perivascular Delivery of Basic Fibroblast Growth Factor in Patients Undergoing Coronary Bypass Surgery, Nov. 2, 1999, Circulation: 1865-1871			
	C70	TSUTSUMI et al., Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation, Oct. 1999, J. Clinical Invest. 104(7):925-935			
	C71	NIEBAUER et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, 1999, Circulation 100:1830-1835			
	C72	WOLF et al., Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury, March 1995, J. Vasc. Surg. 21:499-504			
	C73	HARRISON, Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis, 1991, J. Am. Coll. Cardiol. 17:71B-76B			
	C74	SMITH et al., Tissue plasminogen activator release in vivo in response to vasoactive agents, Oct, 1985, Blood 66(4):835-839			
	C75	FURBERG et al., Effect of lovastatin on early carotid atherosclerosis and cardiovascular events, Oct. 1994, Circulation 90(4): 1679-1687 (ABSTRACT)			
	C76	HENDRIKX et al., New Na <sup>+</sup> -H <sup>+</sup> exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca <sup>2+</sup> overload in isolated perfused rabbit heart, June 1994, Circulation 89(6):2787-2798 (ABSTRACT)			
	C77	JUKEMA et al., Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels, 1995, Circulation 91:2528-2540 (ABSTRACT)			
	C78	WATANABE et al., Randomized, double-blind, placebo-controlled study of supplemental vitamin E on attenuation of the development of nitrate tolerance, Oct. 1997, Circulation 96(8):2545-2550			
	C79	FELDMAN et al., Microfabricated Device for Intravascular Delivery, 1998, J. Am. Coll. Card. 31(2): 351A (870-6)			
	C80	MOLLACE et al., Evidence that L-arginine possesses proconvulsant effects mediated through nitric-oxide, 1991, Neuroreport 2(5):269-272 (ABSTRACT)			
	C81	CONTE et al., Press-coated tablets for time-programmed release of drugs, 1993, Biomaterials 14(13):1017-1023			
	C82	FEELISCH et al., Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells, 1991, Biochem. and Biophys. Res. Comm. 180:Nc:286-293			
	C83	LIEBERMAN et al., Pharmaceutical Dosage Forms: Tablets, 2nd ed., 1990 (TOC)			
	C84	GENNARO et al. eds., Remington's Pharmaceutical Sciences, 18th ed., 1990, Mack Pub. Co. (TOC)			
	C85	O'DRISCOLL et al., Simvastatin, an HMG-Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month, 1997, Circulation 95:1126-1131 (ABSTRACT)			
	C86	LUSCHER et al., Lipids and endothelial function: effects of lipid lowering and other therapeutic interventions, 1996, Curr. Op. Lipid. 7:234-240			
	C87	SEARLES et al., The interaction of nitric oxide, bradykinin, and the angiotensin II type 2 receptor: lessons learned from transgenic mice, Oct. 1999, J. Clin. Investigation 104(8):1013-1014			
	C88	MUSCELLA et al., Angiotensin II Stimulates the Na <sup>+</sup> /H <sup>+</sup> Exchanger in Human Umbilical Vein Endothelial Cells Via AT1 Receptor, 1999, Life Sci. 65(22):2385-2394			
	C89	DINERMAN et al., Molecular Mechanisms of Nitric Oxide Regulation, 1993, Circul. Res. 73(2):217-222			